ClinicalTrials.gg
CompletedNCT04920786TB006SADUpdated Dec 9, 2024

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

A Phase 1 interventional study of TB006 and Sterile saline (Placebo) in Alzheimer Disease, sponsored by TrueBinding, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by TrueBinding, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
985th of 1,609
48 · median 73
Started
2021
with 144 others
Phase 1
304 of 1,940
31 open now
Registered
1,329th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 985th largest by enrollment of the 1,609 interventional ones that give a count, is one of 145 that started in 2021, is one of 304 in phase 1, and was the 1,329th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.

Read the detailed description

The TB006 nonclinical pharmacology program establishes its potential as a therapeutic agent for AD. Overall, the data suggest the potential for beneficial therapeutic effects of TB006 in addressing underlying pathology and ameliorating the course of AD. The preclinical safety profile of TB006 further supports the clinical investigation of TB006. This is a Phase 1 SAD study in healthy adult subjects. The study will evaluate the safety, tolerability, and PK of single doses of TB006, administered as an IV infusion over 1 hour.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer Disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers, male or female 18-55 at the time of
  • In good health as determined by the principal investigator
  • Body weight of ≥ 50 kg and within the range 18-30 kg/m2 (inclusive).
  • Chinese subjects are eligible to be included in the study if all of the following criteria apply in addition to the above: Must have been born in China, with 2 Chinese biological parents and 4 Chinese grandparents as confirmed by interview; Must have lived no more than 10 years outside of China; Must not have changed their lifestyle or habits significantly, including diet, since leaving China.

Exclusion criteria

Exclusion Criteria:

  • Any current history of disease in the opinion of the investigator or receiving maintenance medications on a daily basis.
  • Any active or unstable clinically significant medical or psychiatric condition as judged by the investigator.
  • Smokes cigarettes or uses other nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers), and has done so in the 3 months prior to screening.
  • Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of > 20 units for males or > 16 units for females. One unit is equivalent to 8 glasses of alcohol: a half pint (∼240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    TB006 70 mg - 5000 mg IV

    TB006 infused intravenously over 1 hour

    Drug: TB006

  • Placebo comparator
    Placebo

    0.9% normal saline infused intravenously over 1 hour

    Other: Sterile saline (Placebo)

Interventions

  • DrugTB006

    TB006

  • OtherSterile saline (Placebo)

    Sterile saline

06

What researchers measure

Primary outcomes

  1. Number of subjects and rate of treatment-emergent adverse events, graded by CTCAE Version 5.0, by dose group and all active treatment vs. placebo

    To measure the incidence of AEs and SAEs, clinical laboratory parameters, and vital signs until Day 75 after dosing.

    Time frame: Day1-Day 75

  2. To determine the single-dose PK profile of TB006 in healthy adult subjects

    PK parameters derived by noncompartmental analysis using the TB006 plasma concentration-time data

    Time frame: Through day 75

  3. To determine the MTD of single doses of TB006 in healthy adult subjects

    Dose-response relationship of AEs and SAEs, and other safety outcomes

    Time frame: Through day 75

Secondary outcomes

  1. Pharmacokinetic (PK) profile/parameters: Area under the plasma concentration versus time curve (AUC) through Day 29

    PK:AUC D0-D29

    Time frame: Through Day 75

  2. Pharmacokinetic (PK) profile/parameters: Area under the plasma concentration versus time curve (AUC)

    PK: AUC D0-∞

    Time frame: Through Day 75

  3. Pharmacokinetic (PK) profile/parameters: Maximum observed plasma concentration

    PK: Cmax

    Time frame: Through Day 75

  4. Pharmacokinetic (PK) profile/parameters: Time at which maximum plasma concentration occurs

    PK: tmax

    Time frame: Through Day 75

  5. Pharmacokinetic (PK) profile/parameters: terminal elimination phase half life

    PK: t(1/2)

    Time frame: Through Day 75

  6. Pharmacokinetic (PK) profile/parameters: total clearance

    PK: CL

    Time frame: Through Day 75

  7. Pharmacokinetic (PK) profile/parameters: volume of distribution

    PK: Vd

    Time frame: Through Day 75

  8. Pharmacokinetic (PK) profile/parameters: Extent of CSF distribution as estimated by TB006 CSF concentrations

    PK: CSF

    Time frame: Through Day 75

  9. Safety and tolerability

    Number of subjects and rate of treatment-emergent adverse events, graded by CTCAE Version 5.0, by dose group and all active treatment vs. placebo in non-Chinese healthy and Chinese healthy subjects

    Time frame: Through Day 75

  10. Anti-TB006 antibodies

    Number and rate of subjects who develop anti-TB006 antibodies

    Time frame: Through Day 75

07

Study locations

1 site
  • Collaborative Neuroscience Research, LLC (CNS)
    Long Beach, California 90806, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in May 2022, 11 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 11 months is close to that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2021
First posted
Jun 10, 2021
StartActual
Jun 1, 2021
Primary completionActual
May 3, 2022
CompletionActual
May 3, 2022
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04920786
Lead sponsor
TrueBinding, Inc.
Responsible party
Sponsor
First posted
Jun 10, 2021
Start date
Jun 1, 2021
Primary completion
May 3, 2022
Completion
May 3, 2022
Last update
Dec 9, 2024

Study contacts

George Haig, PharmD
study director · TrueBinding, Inc.
David Walling, MD
principal investigator · Collaborative Neuroscience Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TB006

Start the discussion